MHRA

MHRA Licenses Brensocatib for Non-Cystic Fibrosis Bronchiectasis

The MHRA has granted a marketing authorisation for brensocatib (Brinsupri), the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older. This marks a significant advancement in treatment options for NCFB patients in the UK.

MHRA Class 2 Medicines Recall: KidNaps Melatonin Oral Solution

The MHRA has issued a Class 2 medicines recall for all batches of KidNaps Melatonin 1mg in 1ml Oral Solution due to out-of-specification stability results. Sterling Pharmaceuticals Ltd and Veriton Pharma Ltd are conducting the recall at the wholesaler and pharmacy level.

MHRA Statement on PATHWAYS Puberty Blocker Trial Safety

The MHRA has issued a statement regarding the PATHWAYS puberty blocker trial, expressing concerns about participant wellbeing and initiating scientific dialogue with the trial sponsor, King's College London. The agency is applying high scrutiny to ensure the safety of potential child and young person participants.

MHRA Approves Zanidatamab for HER2+ Biliary Tract Cancer

The MHRA has approved zanidatamab (Ziihera) for adult patients with HER2-positive biliary tract cancer that has progressed after previous treatment. This approval provides a new treatment option for a specific patient population with an unmet clinical need.

MHRA: UK Medical Device Testing Hits Record High, Backs AI

The UK's MHRA reported a 17% increase in approved medical device clinical investigations in 2025. The agency is implementing measures to support innovation, including a fee waiver pilot for small firms and enhanced support for AI and neurotechnology.

MHRA Medical Device Safety Notices

The MHRA has issued a list of eight medical device safety notices published between February 9-13, 2026. These notices cover various devices including ventilator circuits, tissue reconstructive material, and PET/CT scanners. The MHRA publishes these for informational purposes.

MHRA Consultation on Indefinite Recognition of CE-Marked Medical Devices

The MHRA has launched a consultation on proposals for the indefinite recognition of CE-marked medical devices in Great Britain. The consultation seeks feedback on extending current transitional arrangements and introducing an international reliance route to ensure continued supply and patient access to medical technologies. The deadline for feedback is April 10, 2026.

MHRA Consultation on CE Marked Medical Device Recognition

The MHRA has launched a consultation on proposals for the indefinite recognition of CE-marked medical devices in Great Britain. The consultation seeks views on extending transitional arrangements for MDD-compliant devices and indefinitely recognising EU MDR/IVDR compliant devices, with a comment deadline of April 10.

MHRA Seizes 20 Million Illegal ED Pills, Warns Against Online Buys

The MHRA announced the seizure of nearly 20 million illegal erectile dysfunction pills between 2021 and 2025, including 4.4 million in 2025 alone. The agency is warning the public against purchasing unauthorized medicines online due to significant health risks.

MHRA Restricts Chikungunya Vaccine IXCHIQ Use

The MHRA has introduced additional restrictions on the use of the Chikungunya vaccine IXCHIQ. The vaccine is now restricted to adults aged 18-59 without specific pre-existing health conditions, following reports of serious adverse reactions, including fatalities. Healthcare professionals must conduct a benefit-risk assessment before administration.